Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Song

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Journal of the American Academy of Dermatology|June 29, 2026
Adalimumab Biosimilars and Access Barriers in DermatologySimona A Alomary, Nicole J Baker, Anisah Alladeen, et al.
Journal of Lipid Research|January 3, 2006
Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemiaBradley E Aouizerat, Mary B Engler, Yanina Natanzon, et al.
Dermatology and Therapy|October 26, 2025
Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16Eingun James Song, Benjamin Ehst, Brad Glick, et al.
Circulation|June 16, 2005
Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemiaJing Hua, Lawrence W Dobrucki, Mehran M Sadeghi, et al.
Metabolism: Clinical and Experimental|November 18, 2008
Genetic variation in phospholipid transfer protein modulates lipoprotein profiles in hyperalphalipoproteinemiaMary B Engler, Clive R Pullinger, Mary J Malloy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findingsRichard B Warren, Melinda Gooderham, Edward Lain, et al.
Dermatology and Therapy|June 2, 2025
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, et al.
NEJM Evidence|November 5, 2025
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact SitesMelinda Gooderham, Edward Lain, Robert Bissonnette, et al.
Circulation|November 9, 2005
Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodelingHaili Su, Francis G Spinale, Lawrence W Dobrucki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumorsAnthony W Tolcher, Wells A Messersmith, Stanislaw M Mikulski, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of the American Academy of Dermatology|June 29, 2026
Adalimumab Biosimilars and Access Barriers in DermatologySimona A Alomary, Nicole J Baker, Anisah Alladeen, et al.
Journal of Lipid Research|January 3, 2006
Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemiaBradley E Aouizerat, Mary B Engler, Yanina Natanzon, et al.
Dermatology and Therapy|October 26, 2025
Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16Eingun James Song, Benjamin Ehst, Brad Glick, et al.
Circulation|June 16, 2005
Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemiaJing Hua, Lawrence W Dobrucki, Mehran M Sadeghi, et al.
Metabolism: Clinical and Experimental|November 18, 2008
Genetic variation in phospholipid transfer protein modulates lipoprotein profiles in hyperalphalipoproteinemiaMary B Engler, Clive R Pullinger, Mary J Malloy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findingsRichard B Warren, Melinda Gooderham, Edward Lain, et al.
Dermatology and Therapy|June 2, 2025
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, et al.
NEJM Evidence|November 5, 2025
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact SitesMelinda Gooderham, Edward Lain, Robert Bissonnette, et al.
Circulation|November 9, 2005
Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodelingHaili Su, Francis G Spinale, Lawrence W Dobrucki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumorsAnthony W Tolcher, Wells A Messersmith, Stanislaw M Mikulski, et al.
Pageof 10